Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5943
    +0.0006 (+0.11%)
     
  • NZD/EUR

    0.5547
    +0.0001 (+0.02%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.73
    -0.08 (-0.10%)
     
  • GOLD

    2,330.00
    -8.40 (-0.36%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,144.12
    -57.15 (-0.33%)
     
  • NIKKEI 225

    37,886.47
    -573.61 (-1.49%)
     
  • NZD/JPY

    92.3210
    +0.2060 (+0.22%)
     

How Jazz’s Erwinaze, Defitelio, and Prialt Performed in 3Q17

In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenue of $49 million, which reflected a rise of ~14% on a year-over-year (or YoY) basis.